Breaking News Instant updates and real-time market news.

PFE

Pfizer

$42.99

0.95 (2.26%)

, BMY

Bristol-Myers

$46.88

1.76 (3.90%)

18:13
01/05/19
01/05
18:13
01/05/19
18:13

Trump says drug makers 'not living up' to commitments on pricing

In a tweet, President Donald Trump said that, "Drug makers and companies are not living up to their commitments on pricing. Not being fair to the consumer, or to our Country!" Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).Reference Link

PFE

Pfizer

$42.99

0.95 (2.26%)

BMY

Bristol-Myers

$46.88

1.76 (3.90%)

SNY

Sanofi

$42.87

0.41 (0.97%)

AZN

AstraZeneca

$39.18

0.84 (2.19%)

NVS

Novartis

$85.88

1.1 (1.30%)

MRK

Merck

$76.26

2.22 (3.00%)

JNJ

Johnson & Johnson

$127.80

1.99 (1.58%)

RHHBY

Roche

$0.00

(0.00%)

GSK

GlaxoSmithKline

$38.62

0.76 (2.01%)

LLY

Eli Lilly

$114.65

3.36 (3.02%)

  • 05

    Jan

  • 06

    Jan

  • 06

    Jan

  • 07

    Jan

  • 07

    Jan

  • 11

    Jan

  • 14

    Jan

  • 17

    Jan

  • 22

    Jan

  • 24

    Jan

  • 27

    Jan

  • 28

    Jan

  • 28

    Jan

  • 29

    Jan

  • 16

    Feb

  • 18

    Feb

  • 11

    Mar

  • 18

    Mar

  • 22

    Mar

  • 11

    Apr

  • 28

    Apr

  • 18

    May

  • 20

    May

PFE Pfizer
$42.99

0.95 (2.26%)

12/31/18
CANT
12/31/18
NO CHANGE
Target $53
CANT
Overweight
Doctors impressed by tanezumab data, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen says that investors she's spoken with are expecting the data for Pfizer (PFE) and Eli Lilly's (LLY) tanezumab in the first half of 2019 to be similar to or worse than what was seen in the first Phase 3 data set reported on October 23. However, physicians are impressed by the data and do not believe the rapidly progressive osteoarthritis imbalance would impact their desire to prescribe tanezumab if it is approved, Chen tells investors in a research note. The analyst believes the safety for tanezumab will be better than expected and that the drug could replace opioids for the treatment of pain. If that is right, peak sales potential of tanezumab could be billions of dollars, and drive upside to modest expectations for the drug, says the analyst. She keeps an Overweight rating on Pfizer with a $53 price target.
12/28/18
BTIG
12/28/18
NO CHANGE
Target $190
BTIG
Buy
Sarepta's recent weakness represents 'buying opportunity', says BTIG
BTIG analyst Timothy Chiang kept his Buy rating and $190 price target on Sarepta (SRPT), noting that while the stock was among the best performing biotech names this year, its recent weakness represents a "potential buying opportunity". The analyst believes that the company's AAVrh74 micro-dystrophin gene therapy for the treatment of Duchenne Muscular Dystrophy program leads those of Pfizer (PFE) and Solid Biosciences (SLDB) and expects Sarepta to reach about $2B in peak U.S. sales by 2024.
12/27/18
ARGS
12/27/18
NO CHANGE
Target $47
ARGS
Buy
GlaxoSmithKline's high dividend yield 'attractive', says Argus
Argus analyst John Eade kept his Buy rating and $47 price target on GlaxoSmithKline (GSK) with a positive view on its planned joint venture with Pfizer (PFE) combining the companies' consumer businesses. The analyst expects the transaction to boost GlaxoSmithKline shares in the next 2-3 years. Eade also cites the company's 5.2% dividend yield, which he sees as "attractive in a low-interest-rate environment."
01/03/19
01/03/19
INITIATION

Pfizer initiates Phase 2b/3 clinical trial for PF-06651600
Pfizer announced the initiation of a Phase 2b/3 clinical trial for its oral JAK3 inhibitor, PF-06651600, for the treatment of patients with moderate to severe alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, face, or body, and currently has no approved therapies. Based on the totality of the data and the emerging clinical profile, PF-06651600 was granted Breakthrough Therapy designation from FDA for the treatment of alopecia areata in September 2018. PF-06651600 will also continue to be evaluated for rheumatoid arthritis, Crohn's disease and ulcerative colitis.
BMY Bristol-Myers
$46.88

1.76 (3.90%)

01/04/19
BARD
01/04/19
UPGRADE
Target $92
BARD
Outperform
Baird upgrades Celgene to Outperform, says deal discount looks high
As reported previously, Baird analyst Brian Skorney upgraded Celgene (CELG) to Outperform from Neutral. The analyst believes the current price discount to the Bristol-Myers (BMY) deal price does not makes sense based on the probability of the deal closing in the high $90's. He attributes a 35-40% probability of the deal falling through, but he is more bullish on the deal as management is now shown to be willing sellers. Skorney has a $92 price target on Celgene shares, which are up about 2% in pre-market trading to $82 per share.
01/04/19
WELS
01/04/19
NO CHANGE
Target $84
WELS
Market Perform
Celgene price target cut to $84 from $90 at Wells Fargo
Wells Fargo analyst Jim Birchenough maintained a Market Perform rating on Celgene (CELG) but cut his price target to $84 following yesterday's proposed acquisition by Bristol-Myers (BMY). In a research note to investors, Birchenough says he continues to see fundamental risk to both Celgene value and deal closing with poor visibility on long-term growth for the combined company and risk to ongoing Revlimid patent litigation. With the debate on Revlimid generic timing and impact likely to remain on overhang, the analyst believes that the proposed acquisition gives greater leverage to generics, reduces the likelihood of a reasonable settlement and complicates any settlement process.
01/04/19
EDJN
01/04/19
DOWNGRADE
EDJN
Hold
Bristol-Myers downgraded to Hold from Buy at Edward Jones
01/04/19
01/04/19
DOWNGRADE

Outperform
BeiGene downgraded to Outperform at CLSA as Celgene goes 'from friend to foe'
As previously reported, CLSA analyst David Li downgraded BeiGene to Outperform from Buy following the news yesterday of Bristol-Myers' (BMY) proposed acquisition of Celgene (CELG) in a note titled "From friend to foe." He thinks Celgene is unlikely to continue to cooperate with BeiGene on its PD-1 after the deal goes through and also worries about the three commercialized products licensed from Celgene and about the company selling out of its BeiGene stake, he tells investors. He lowered his price target on BeiGene shares to HK$89.86 from HK$121.34.
SNY Sanofi
$42.87

0.41 (0.97%)

01/03/19
SBSH
01/03/19
NO CHANGE
Target $70
SBSH
Buy
Citi calls MyoKardia 'more interesting long term play' after Sanofi news
Citi analyst Mohit Bansal says that while some might see Sanofi (SNY) giving back all rights back to MyoKardia (MYOK) as a negative, he sees "significant strategic implications in longer term." The move gives MyoKardia more freedom to employ its "Divide and Conquer" precision strategy, Bansal tells investors in a research note titled "Full control makes MYOK an interesting long term play." The analyst also points out that Sanofi's decision was related to wanting U.S. control over Mavacamten, and is not related to the profile of the products. Bansal lowered his price target for MyoKardia to $70 from $90 and keeps a Buy rating on the shares.
01/03/19
MSCO
01/03/19
NO CHANGE
Target $70
MSCO
Overweight
MyoKardia shares oversold on Sanofi collaboration end, says Morgan Stanley
Morgan Stanley analyst Jeffrey Hung said MyoKardia (MYOK) management emphasized that Sanofi (SNY) wanted greater economics and maintained that efficacy and safety did not factor into Sanofi's decision to end their collaboration. His base case assumption is that MyoKardia will find another partner after more mature data are reported and he thinks the shares have been oversold following yesterday's announcement, Hung tells investors. He trimmed his price target on the stock to $70 from $72, but keeps an Overweight rating, stating that he believes the Phase 2 mavacamten data were promising and sees multiple catalysts over the next year.
12/11/18
GABE
12/11/18
NO CHANGE
GABE
Buy
Gabelli sees Clovis as likely takeout target, top biotech pick in 2019
Gabelli analyst Jing He highlights Clovis (CLVS) as his top biotech pick in 2019. With the Tesaro (TSRO) acquisition by GlaxoSmithKline (GSK), Clovis will become the only standalone PARP, which the analyst believes makes it the most likely takeout target in 2019. He continues to believe Bristol-Myers (BMY), Sanofi (SNY) and Roche (RHHBY) to be the most interested buyers. The analyst reiterates a Buy rating on Clovis' shares.
12/11/18
12/11/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AT&T (T) upgraded to Buy from Neutral at Citi with analyst Michael Rollins saying he expects AT&T to further benefit from the "measured" promotional environment in wireless, while improving its competitive position from FirstNet and the marketing of its network enhancements, branded 5G Evolution. 2. Sanofi (SNY) upgraded to Buy from Hold at Jefferies with analyst Peter Welford saying he believes European large-cap pharmaceuticals are entering a period of sustained earnings momentum which should justify valuations above the historic average for the sector. 3. Total (TOT) upgraded to Buy from Neutral at BofA/Merrill. 4. Zynga (ZNGA) upgraded to Outperform from Neutral at Macquarie. 5. Allstate (ALL) upgraded to Hold from Sell at Edward Jones. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AZN AstraZeneca
$39.18

0.84 (2.19%)

12/14/18
12/14/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Outperform at Wedbush and a Hold at Deutsche Bank. 2. New York Times (NYT) initiated with an Outperform at Evercore ISI. 3. Ford (F) and General Motors (GM) were initiated with a Buy at Deutsche Bank, while Autoliv (ALV) was initiated with a Sell. 4. AstraZeneca (AZN) initiated with a Buy at SunTrust while GlaxoSmithKline (GSK) was initiated with a Hold. 5. DaVita (DVA) initiated with an Overweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/13/18
RHCO
12/13/18
INITIATION
RHCO
SunTrust sees oncology fueling growth for AstraZeneca through 2022
SunTrust analyst John Boris initiated AstraZeneca with a Buy rating and $48 price target, saying oncology should fuel growth through 2022 -- supported by label expansion of its in-line products and new launches -- as well as growth accelerated by 2019 pipeline catalysts.
12/13/18
RHCO
12/13/18
INITIATION
Target $48
RHCO
Buy
AstraZeneca initiated with a Buy at SunTrust
SunTrust analyst John Boris started AstraZeneca with a Buy rating and $48 price target.
12/20/18
WELS
12/20/18
NO CHANGE
WELS
Drug industry facing 'brave new world' with drug price scrutiny, says Wells
After Reuters reported that nearly 30 drugmakers are planning to raise the prices of their medicines in the U.S. starting in January, including Novartis (NVS), Bayer (BAYRY), GlaxoSmithKline (GSK), Amgen (AMGN), AstraZeneca (AZN), Biogen (BIIB) and Allergan (AGN), Wells Fargo analyst David Maris told investors in a research note that he has repeatedly highlighted how the practice of drug price increases is a risk for the industry, and believes the latest actions by these manufacturers will be "front and center" for the Trump administration heading towards an election year. He also expects to see increased political and legislative pressure on drug prices as Democrats take over the House in January, and continues to believe that the drug industry is facing a "brave new world" with greater scrutiny of drug prices, lower price increases vs. historical levels, and as a result potentially lower profit margins.
NVS Novartis
$85.88

1.1 (1.30%)

12/18/18
COWN
12/18/18
NO CHANGE
COWN
Outperform
Cowen sees Sandoz deal as reinforcing Tilray's competitive positioning
Tilray's (TLRY) expanded global partnership with Novartis (NVS) division Sandoz can not only help expand its reach with pharmacists, physicians and distributors, it can also help Tilray capture early share in new medical cannabis markets as they come online, Cowen analyst Vivien Azer tells investors in a research note. Further, the analyst believes the partnership also helps legitimize cannabis in international markets, which could help influence countries considering medical cannabis legalization. Azer estimates international will represent 15% of Tilray's revenue in fiscal 2020 and 22% in fiscal 2021. Not only does the deal allow Tilray to expand geographic reach, but also to grow at scale, says Azer. And most notably, the Sandoz deal reinforces Tilray's competitive positioning, adds the analyst, who keeps an Outperform rating on the shares with a $150 price target. The stock in morning trading is up 9%, or $5.98, to $71.87.
12/11/18
JEFF
12/11/18
INITIATION
Target $105
JEFF
Buy
Novartis assumed with a Buy at Jefferies
Jefferies analyst Peter Welford assumed coverage of GNovartis with a Buy rating and $105 price target. The analyst is positive on the European large-cap Pharma space "as it enters a period of sustained earnings momentum."
01/02/19
JPMS
01/02/19
DOWNGRADE
JPMS
Underweight
Novartis downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Richard Vosser downgraded Novartis to Underweight with a price target of CHF 89. The analyst has concerns over the company's pipeline and believes the shares are close to fair value.
MRK Merck
$76.26

2.22 (3.00%)

11/19/18
WELS
11/19/18
NO CHANGE
WELS
Pfizer price hikes may bring industry scrutiny, says Wells Fargo
Pfizer's (PFE) plans to raise prices on a host of medicines may put the drug industry "further in the crosshairs of an administration and Congress that is set on lowering drug prices," Wells Fargo analyst David Maris tells investors in a research note. The analyst points out that Pfizer earlier this year was criticized by the Trump administration for drug price increases, and as a result, it rolled the price increases back. However, Pfizer's new price increases "are not egregious" and its advance warning may be an attempt to see if minor price increases will also bring the administration's rebuke, says Maris. Nonetheless, given how public the administration's previous rebuke was, the analyst thinks Pfizer's confirmation Friday could "enflame the debate around drug pricing, especially since it comes less than two weeks following an election that resulted in Democrat control of the House with many having run on a drug-price-controls/Medicare-for-All platforms." Other large drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
11/06/18
PIPR
11/06/18
NO CHANGE
Target $3
PIPR
Overweight
OncoSec price target lowered to $3 from $5 at Piper Jaffray
After OncoSec (ONCS) reported preliminary Phase 2b KEYNOTE-695 data for Tavo combined with Merck's (MRK) Keytruda in PD-1 refractory melanoma patients, Piper Jaffray analyst Edward Tenthoff said the data, while early, show evidence of clinical activity, adding that he believes duration of response data will be important. However, OncoSec shares are down 52% today, which Tenthoff attributes to the lower response rate compared to prior data in different patients. The analyst keeps an Overweight rating on OncoSec shares, but lowered his price target on the stock to $3 from $5 as he pushed out his approval projections for Tavo by one year in the U.S. and Europe.
10/31/18
SBSH
10/31/18
NO CHANGE
Target $84
SBSH
Buy
Merck price target raised to $84 from $79 at Citi
Citi analyst Andrew Baum raised his price target for Merck to $84 and reiterates a Buy rating on the shares. The analyst says his 20%-plus above consensus non-GAAP earnings estimates beyond 2022 are driven by a continued view that the market underestimates Merck's market share in the PDx and PARP spaces with Keytruda and Lynparza respectively.
10/25/18
WELS
10/25/18
NO CHANGE
WELS
Wells Fargo says Trump speech today won't be end of drug pricing proposals
Wells Fargo analyst David Maris notes that Politico and other media outlets are reporting that President Donald Trump will propose several new initiatives to address high drug prices when he speaks later today at the U.S. Department of Health and Human Services. Maris thinks Trump's focus will be on how other countries are "freeloading" on U.S. innovation with lower negotiated pricing, stating that news reports make it appear that the administration is targeting the industry for action, rather than other countries to raise their spending. While Maris acknowledges the timing of the speech being near the mid-term elections, he believes these proposals are simply the follow-though of earlier promises. He also expects this is not the end of proposals to address the issue of U.S. drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
JNJ Johnson & Johnson
$127.80

1.99 (1.58%)

01/04/19
BTIG
01/04/19
NO CHANGE
Target $17
BTIG
Buy
Veracyte price target raised to $17 from $15 at BTIG
BTIG analyst Sung Ji Nam raised his price target on Veracyte (VCYT) to $17 and kept the Buy rating on the shares after its announced long term partnership with Johnson & Johnson (JNJ) yesterday. The analyst says the collaboration aims to accelerate the development of the first nasal swab test for early lung cancer detection and involve the two companies sharing existing data and samples from clinical studies. Sung Ji Nam states that the deal should lead to acceleration of next -gen Percepta launch, adding that the nasal swab test development could quadruple the company's total addressable market value in the U.S. alone.
01/02/19
SBSH
01/02/19
NO CHANGE
SBSH
Citi makes four rating changes in Medical Devices, 'warning up' to J&J
Citi analyst Amit Hazan issued his 2019 preview for Medical Devices, which included four rating changes. The analyst upgraded both Zimmer Biomet (ZBH) and Baxter International (BAX) to Buy from Neutral, downgraded Medtronic (MDT) to Neutral from Buy and downgraded Abbott Laboratories (ABT) to Sell from Neutral. He also kept Buy ratings on Intuitive Surgical (ISRG) and Boston Scientific (BSX), but adds he's "relatively more cautious." Further, Hazan kept a Sell rating on Edwards Lifesciences (EW) and says he's "warming up" to Neutral-rated Johnson & Johnson (JNJ). The analyst expects "fairly stable" fundamentals for the group in 2019, with "modest slowdowns" in organic sales and earnings growth.
12/20/18
WELS
12/20/18
NO CHANGE
WELS
Outperform
No change in talc litigation risk for Johnson & Johnson, says Wells Fargo
Wells Fargo analyst Larry Biegelsen notes that the NY Times reported that Johnson & Johnson has lost its bid to overturn the $4.7B in a talc trial in St. Louis in July 2018. After checking with the company, the analyst is "able to confirm" that the decision relates to the trial judge denying Johnson & Johnson's post trial motion to set aside the $4.7B verdict. Biegelsen understands that the company had to file this motion in order to file its actual appeal of the decision with the appellate court. As such, he believes the judge's decision should not materially affect the overall talc situation for Johnson & Johnson. Wells Fargo has an Outperform rating on the shares.
01/04/19
CANT
01/04/19
NO CHANGE
Target $100
CANT
Overweight
Cantor Fitzgerald analysis suggests others could bid for Celgene
Cantor Fitzgerald analyst Alethia Young reiterates an Overweight rating on Celgene (CELG) with a $100 price target after the company reached an agreement to be acquired by Bristol-Myers Squibb (BMY). Bristol "likely got a good deal, although Celgene has intellectual property and pipeline uncertainties that are key moving pieces," Young tells investors in a research note. Her estimated net present value for Celgene is $80B, assuming some cost synergies, versus the $74B equity valuation in the Bristol deal, excluding the contingent value rights. Young's analysis indicates that companies like Amgen (AMGN) and Johnson & Johnson (JNJ) "could potentially achieve greater commercial synergies." However, the analyst thinks Celgene shareholders "may be satisfied with the current deal after quite a roller-coaster over the past 18 months."
RHHBY Roche
$0.00

(0.00%)

12/18/18
BERN
12/18/18
NO CHANGE
Target $288
BERN
Market Perform
Biogen drops after Bernstein sees potential downside of $100 on Q1 risks
Bernstein analyst Aaron Gal earlier today lowered his price target for Biogen (BIIB) to $288 from $341 while keeping a Market Perform rating on the shares. The Biogen "debate" revolves primarily around three elements: the durability of the existing franchises, the value of the company's Alzheimer's opportunity, and the potential of the pipeline to generate new drugs, Gal wrote in a research note. He believes the stock's current risk/reward balance "captures these dynamics." In Q1 of 2019, however, Biogen is facing "two significant risks," says the analyst. These are the inter partes review institution decision on its biggest drug, Tecfidera, and futility analyses of amyloid beta drugs - Roche's (RHHBY) crenezumab and potentially Biogen's own aducanumab, according to Gal. The analyst views Biogen's near-term risk/reward as "sharply negative." If a review of Tecfidera is instituted and one of the amyloid beta trials is stopped for futility, the stock "can easily" trade $100 per share lower, Gal believes. Even if one of these events goes against the company, the analyst thinks the Biogen can drop $30-$80 per share. On the other hand, passing both risks will likely only have "moderate upside" of around $30 per share as "both are assumed to be positive in sell-side consensus," Gal writes. He keeps a Market Perform rating on Biogen, which is down 7%, or $21.45, to $291.66 in afternoon trading.
12/20/18
PIPR
12/20/18
NO CHANGE
Target $400
PIPR
Overweight
Survey shows 'solid fundamentals' for Biogen MS franchise, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Biogen (BIIB) with a $400 price target after surveying 100 neurologists. The survey feedback shows "solid fundamentals" for the company's multiple sclerosis portfolio, Raymond tells investors in a research note. He admits, however, that many investors are preoccupied with Tecfidera's intellectual property situation. Nonetheless, neurologists reported meaningful share gains for Tecfidera and Tysabri this quarter, says the analyst. Raymond believes worries over the impact to Biogen's multiple sclerosis franchise from Roche's (RHHBY) Ocrevus launch "may be behind us."
12/17/18
PIPR
12/17/18
NO CHANGE
PIPR
Proteostasis deal with Genentech strenghtens balance sheet, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $14 price target on Proteostasis (PTI), noting the company announced an agreement with Roche's (RHHBY) Genentech to license small molecule modulators of an undisclosed target that lie outside of Cystic Fibrosis, which makes the company eligible for $100M in upfront and milestone payments plus royalties. Tenthoff sees this deal strengthening Proteostasis' balance sheet. Additionally, Tenthoff is optimistic on Proteostasis' TripleRx combo, and expects full Phase I TripleRx data in Q1 of 2019. Longer term, the analyst anticipates TripleRx approval in 2021, with global sales of $2.0B by 2026.
01/02/19
JPMS
01/02/19
NO CHANGE
JPMS
JPMorgan adds Novo Nordisk to Analyst Focus List, removes Roche
JPMorgan analyst Richard Vosser added Novo Nordisk (NVO) to his firm's European Analyst Focus List while removing Roche (RHHBY).
GSK GlaxoSmithKline
$38.62

0.76 (2.01%)

12/14/18
LEER
12/14/18
NO CHANGE
LEER
Outperform
Tesaro proxy documents point to interest in PARP economics, says Leerink
Leerink analyst Andrew Berens noted that GlaxoSmithKline (GSK) and Tesaro (TSRO) disclosed background details for their deal agreement in a filing this morning. The documents show several parties were interested in a strategic transaction with Tesaro at various points over the last year, though the strategic interest appears to have been driven by Glaxo and one additional company, identified as "Party A", Berens said. It is not clear why the six other contacted parties were not interested in pursuing a strategic transaction, but he thinks Party A's co-promote proposal and the initial interest of other potential acquirers indicates strategic interest in the economics surrounding a PARP. Berens, who continues to see Clovis (CLVS) being well-positioned as the remaining stand-alone PARP-focused company, keeps an Outperform rating on Clovis and Market Perform rating on Tesaro.
LLY Eli Lilly
$114.65

3.36 (3.02%)

12/27/18
ARGS
12/27/18
NO CHANGE
Target $135
ARGS
Buy
Argus sees volume growth, expanded indications as 2019 catalysts for Eli Lilly
Argus analyst David Toung kept his Buy rating and $135 price target on Eli Lilly, saying its 2019 catalysts for upside include anticipated volume growth and expanded indications for existing drugs, along with "potential regulatory approvals". The analyst notes that while the company's mature products are seeing slower sales and face patent expiration and the loss of exclusivity, he also expects Eli Lilly to generate earnings growth from margin expansion. Toung is also confident in 2019 contribution of Eli Lilly's recently launched Olumiant for rheumatoid arthritis, Verzenio for the second-line treatment of breast cancer, and Taltz for active psoriatic arthritis.
12/24/18
BMOC
12/24/18
NO CHANGE
Target $132
BMOC
Outperform
Eli Lilly price target raised to $132 from $124 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Eli Lilly to $132 from $124 and kept his Outperform rating, saying that unlike its peers, the company offers "multiple growth drivers and several pipeline assets that could provide meaningful upside." The analyst anticipates Eli Lilly's annualized revenue and earnings growth of 5% and 16% with "significant upside potential" coming from Tanezumab and Alzheimer's program. Araeil further believes that the company's growth, strong R&D and commercial execution prospects "support its premium valuation."
12/20/18
LEHM
12/20/18
NO CHANGE
Target $120
LEHM
Overweight
Eli Lilly update 'bolsters bullish outlook,' says Barclays
Barclays analyst Geoff Meacham believes Eli Lilly's update yesterday bolstered its bullish outlook. The company's new product growth underscores an attractive investment case, Meacham tells investors in a research note. While the initial 2019 guidance was "solidly ahead of expectations," what is more impressive is the underlying quality, with new products set to drive 45% of 2019's growth outlook, says the analyst. He keeps an Overweight rating on Eli Lilly with a $120 price target.

TODAY'S FREE FLY STORIES

CLDR

Cloudera

$8.47

-0.195 (-2.25%)

14:45
11/13/19
11/13
14:45
11/13/19
14:45
Options
Cloudera call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

DIS

Disney

$145.75

7.19 (5.19%)

14:41
11/13/19
11/13
14:41
11/13/19
14:41
Recommendations
Disney analyst commentary  »

Disney price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$145.31

6.75 (4.87%)

14:38
11/13/19
11/13
14:38
11/13/19
14:38
Hot Stocks
Disney confirms 10M sign-ups for Disney+ since yesterday's launch »

Disney+, the streaming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:35
11/13/19
11/13
14:35
11/13/19
14:35
General news
Fedspeak continues Thursday, headlined by Chair Powell »

Fedspeak continues…

LANC

Lancaster Colony

$154.41

0.11 (0.07%)

14:33
11/13/19
11/13
14:33
11/13/19
14:33
Hot Stocks
Lancaster Colony reelects three incumbent directors and elects one new director »

Lancaster Colony…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

LANC

Lancaster Colony

$154.13

-0.17 (-0.11%)

14:31
11/13/19
11/13
14:31
11/13/19
14:31
Hot Stocks
Lancaster Colony raises dividend to 70c from 65c per share »

Lancaster Colony…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

AXAS

Abraxas Petroleum

$0.29

-0.027 (-8.57%)

14:26
11/13/19
11/13
14:26
11/13/19
14:26
Hot Stocks
Abraxas Petroleum says final decision on 2020 capital budget to be made later »

Abraxas management and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXAS

Abraxas Petroleum

$0.29

-0.027 (-8.57%)

14:26
11/13/19
11/13
14:26
11/13/19
14:26
Earnings
Abraxas reports Q3 adjusted EPS 2c, consensus 3c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBX

Dropbox

$19.14

0.24 (1.27%)

14:25
11/13/19
11/13
14:25
11/13/19
14:25
Options
Dropbox call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 21

    Nov

EBS

Emergent BioSolutions

$55.00

-0.31 (-0.56%)

14:25
11/13/19
11/13
14:25
11/13/19
14:25
Conference/Events
Emergent BioSolutions participates in a conference call with JPMorgan »

SMid Biotech Analyst Fye…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 21

    Nov

TTWO

Take-Two

$119.84

0.84 (0.71%)

, NVDA

Nvidia

$206.44

-3.11 (-1.48%)

14:20
11/13/19
11/13
14:20
11/13/19
14:20
Hot Stocks
Rockstar says 'Red Dead 2' PC stuttering due to issues with Nvidia drivers, GPUs »

Take-Two's (TTWO)…

TTWO

Take-Two

$119.84

0.84 (0.71%)

NVDA

Nvidia

$206.44

-3.11 (-1.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 20

    Nov

  • 21

    Nov

  • 06

    Jan

I

Intelsat

$14.71

-5.68 (-27.86%)

14:20
11/13/19
11/13
14:20
11/13/19
14:20
Recommendations
Intelsat analyst commentary  »

Intelsat selloff appears…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

SQM

SQM

$23.75

-1.15 (-4.62%)

, ALB

Albemarle

$64.60

-0.68 (-1.04%)

14:17
11/13/19
11/13
14:17
11/13/19
14:17
Hot Stocks
Lithium suppliers fall amid inventory glut in China, 'weak' electric car sales »

Shares of Lithium makers…

SQM

SQM

$23.75

-1.15 (-4.62%)

ALB

Albemarle

$64.60

-0.68 (-1.04%)

LTHM

Livent

$7.50

-0.325 (-4.15%)

FMC

FMC Corporation

$96.16

-2.175 (-2.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 21

    Nov

  • 22

    Nov

  • 05

    Dec

  • 06

    Dec

  • 12

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
11/13/19
11/13
14:17
11/13/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
11/13/19
11/13
14:16
11/13/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$9.75

0.145 (1.51%)

14:10
11/13/19
11/13
14:10
11/13/19
14:10
Options
134K contract put spread in Teva rolls puts into put spread »

134K contract put spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

14:07
11/13/19
11/13
14:07
11/13/19
14:07
General news
Treasury Budget data reported »

October Treasury Budget…

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$309.38

0.44 (0.14%)

14:03
11/13/19
11/13
14:03
11/13/19
14:03
Periodicals
U.S., China trade talks hit snag over farm purchases, WSJ reports »

Trade talks between the…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$309.38

0.44 (0.14%)

ADM

Archer Daniels

$42.85

-0.4 (-0.92%)

AGU

Agrium

$0.00

(0.00%)

CF

CF Industries

$46.61

-1.28 (-2.67%)

POT

Potash

$0.00

(0.00%)

ANDE

Andersons

$22.85

-0.36 (-1.55%)

SYT

Syngenta

$0.00

(0.00%)

BG

Bunge

$54.77

-0.99 (-1.78%)

IPI

Intrepid Potash

$2.24

-0.105 (-4.48%)

CMP

Compass Minerals

$55.53

-1.3 (-2.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

  • 19

    Nov

KNX

Knight-Swift

$37.45

-0.445 (-1.17%)

14:00
11/13/19
11/13
14:00
11/13/19
14:00
Options
Calls lead puts 50:1 in Knight Swift Transportation »

Calls lead puts 50:1 in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$309.35

0.41 (0.13%)

13:59
11/13/19
11/13
13:59
11/13/19
13:59
Periodicals
Breaking Periodicals news story on S&P 500, SPDR S&P 500 ETF Trust »

U.S., China trade talks…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$309.35

0.41 (0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLM

Martin Marietta

$256.47

1.18 (0.46%)

13:55
11/13/19
11/13
13:55
11/13/19
13:55
Conference/Events
House Science, Space & Technology Committee to hold a hearing »

The Subcommittee on Space…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

13:55
11/13/19
11/13
13:55
11/13/19
13:55
Conference/Events
House Judiciary Committee to hold a hearing »

The Subcommittee on…

DBX

Dropbox

$18.52

-0.38 (-2.01%)

13:52
11/13/19
11/13
13:52
11/13/19
13:52
Hot Stocks
Dropbox CEO Houston buys $9.57M worth of shares »

Dropbox CEO Andrew…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 21

    Nov

13:45
11/13/19
11/13
13:45
11/13/19
13:45
General news
Treasury Budget to be reported at 14:00 »

October Treasury Budget…

V

Visa

$179.40

-0.39 (-0.22%)

, MA

MasterCard

$277.91

0.8 (0.29%)

13:39
11/13/19
11/13
13:39
11/13/19
13:39
Recommendations
Visa, MasterCard analyst commentary  »

Baird says FTC probe not…

V

Visa

$179.40

-0.39 (-0.22%)

MA

MasterCard

$277.91

0.8 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.